GTx, Inc. (NASDAQ:GTXI) stock declined 14.31% to $1.61. The company on Sept. 24 announced that top line results from the two Phase 3 trials on the effects of enobosarm for the prevention and treatment of muscle wasting in non-small cell lung cancer patients was presented on September 28, 2013, at the European Cancer Congress 2013 […]